Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
INDIVIOR INC. et al v. ALVOGEN PINE BROOK, INC.
Case Number:
2:17-cv-07106
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
Companies
Sectors & Industries:
-
June 24, 2022
Dr. Reddy's Gets $72M In Generic Suboxone Settlement
Indivior, Aquestive and Dr. Reddy's Laboratories have ended their yearslong litigation battle over generic versions of the opioid addiction treatment Suboxone, with the Indian drugmaker on Friday saying it will receive $72 million by April 2024.
-
August 24, 2020
Dr. Reddy's Can Add Antitrust Allegations In Suboxone Row
Dr. Reddy's Laboratories and Alvogen can move forward with antitrust counterclaims against Indivior in a dispute over generic versions of Indivior's opioid addiction treatment Suboxone after a New Jersey federal judge ruled Monday that Indivior was not shielded from liability.
-
January 25, 2019
Indivior Wins Temporary Block On Alvogen Suboxone Generic
Indivior Inc. on Thursday won a bid to temporarily block New Jersey-based Alvogen Pine Brook Inc. from selling a generic version of the opioid addiction treatment drug Suboxone, which is at the center of an ongoing patent row, according to an order from a Garden State federal judge.
-
August 28, 2018
Teva Can't Move IP Suits Over Opioid Treatment Drug To Del.
A New Jersey federal judge on Monday refused to transfer to Delaware a group of Indivior Inc.'s lawsuits that accuse Dr. Reddy's Laboratories, Teva Pharmaceuticals and Alvogen Pine Brook Inc. of pursuing generic versions of brand name opioid addiction treatment drug Suboxone, infringing its patents.